26-Apr-2024
Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertainties
TipRanks (Fri, 26-Apr 2:11 AM ET)
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
Globe Newswire (Thu, 25-Apr 7:00 AM ET)
Globe Newswire (Wed, 24-Apr 10:30 AM ET)
TipRanks (Tue, 23-Apr 6:25 AM ET)
Globe Newswire (Mon, 22-Apr 7:00 AM ET)
Globe Newswire (Wed, 10-Apr 7:00 AM ET)
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
Globe Newswire (Mon, 25-Mar 7:00 AM ET)
Globe Newswire (Fri, 15-Mar 7:00 AM ET)
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
Globe Newswire (Tue, 12-Mar 7:00 AM ET)
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
Globe Newswire (Fri, 1-Mar 7:00 AM ET)
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Bioxcel Therapeutics trades on the NASDAQ stock market under the symbol BTAI.
As of April 26, 2024, BTAI stock price climbed to $2.63 with 255,947 million shares trading.
BTAI has a beta of 0.63, meaning it tends to be less sensitive to market movements. BTAI has a correlation of 0.00 to the broad based SPY ETF.
BTAI has a market cap of $80.42 million. This is considered a Micro Cap stock.
Last quarter Bioxcel Therapeutics reported $376,000 in Revenue and -$.76 earnings per share. This fell short of revenue expectation by $-334,000 and exceeded earnings estimates by $.15.
In the last 3 years, BTAI stock traded as high as $39.00 and as low as $1.91.
The top ETF exchange traded funds that BTAI belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
BTAI has underperformed the market in the last year with a price return of -87.4% while the SPY ETF gained +27.4%. BTAI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -20.5% and -9.3%, respectively, while the SPY returned +4.6% and -0.5%, respectively.
BTAI support price is $2.49 and resistance is $2.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BTAI stock will trade within this expected range on the day.